MNOV Earnings — Medicinova, Inc. Post-ER Performance | BigEarnings
MNOV — Medicinova, Inc.
XNAS
Price$1.36
Market Cap$65.5M
P/E—
52W Range$1.17 – $1.96
Next Earnings2026-08-13
About Medicinova, Inc.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
